Please assess the completion status of the following clinical trial:

Trial Title: Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 65~* Patients with this lymphoma:~  1. CD20 positive diffuse large B-cell lymphoma in relapse or refractory after two prior regimens or after one regimen including autologous stem cell transplantation, or~ 2. CD20 positive mantle-cell lymphoma in relapse or refractory after two prior regimens or after one regimen including autologous stem cell transplantation or~ 3. Other CD20 positive aggressive lymphoma for which an indication of allograft is selected (Burkitt lymphoma, lymphoblastic lymphoma, intra-vascular lymphoma.....) or~ 4. Low grade lymphoma CD20 positive (follicular lymphoma, marginal zone lymphoma) in histological processing or~ 5. Low grade lymphoma CD20 positive for which an indication of allograft is selected~* And sensitive to relapse's treatment~* HLA-matched related or unrelated donor 10/10 or 9/10 with C or DQ mismatch without contra-indication for stem cell mobilization~* ECOG (Eastern Cooperative Oncology Group) \< 2~* Having or not received previously rituximab~* With a chemosensitive relapse NHL (at least partial response \> 50% as defined with cheson criteria (See appendix 5)~* Eligible for an allogenic transplant~* With a signed informed consent (obtained on the screening day at the latest and before any investigation)~* Patient affiliated to or beneficiary of the National Health Service~Exclusion Criteria:~* Patient allografted previously~* History of cancer~* Patient with HIV or HCV positive serology and requiring treatment~* Childbearing or child breastfeeding women~* Women who are pregnant or nursing, or man, in the absence of effective contraception during treatment and up to 12 months after stopping treatment~* Any contraindication to allogenic stem cell transplantation:~* Cardiac insufficiency (ejection fraction \< 50% by echocardiography)~* Respiratory insufficiency defined as DLCO below 50% of the theoretical value~* Renal failure defined as creatinin clearance \< 30 ml/mn~* Hepatic failure defined as a 2-fold increase of bilirubin or transaminases except if due to the lymphoma~* Known hypersensitivity to murine antibodies and other proteins, the active ingredients or any of the ingredients of the products under review~* Patient under the protection of justice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zevalin (Type: EXPERIMENTAL): Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).